Chronic Heart Failure With Reduced Ejection Fraction

Cardiovascular
3
Pipeline Programs
4
Companies
17
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Cytokinetics
CytokineticsSOUTH SAN FRANCISCO, CA
1 program
1
Omecamtiv mecarbilPhase 31 trial
Active Trials
NCT04464525Withdrawn0Est. Nov 2026
Ionis Pharmaceuticals
1 program
1
IONIS-AGT-LRxPhase 21 trial
Active Trials
NCT04836182Completed72Est. Jan 2023
M&
Merck & Co.RAHWAY, NJ
1 program
1
VericiguatPhase 21 trial
Active Trials
NCT06195930Completed106Est. Jul 2024
Bayer
BayerLEVERKUSEN, Germany
1 program
VericiguatN/A5 trials
Active Trials
NCT06632483Active Not Recruiting1,200Est. Apr 2026
NCT06697353Completed4,936Est. Sep 2025
NCT06486844Completed500Est. Aug 2025
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
BayerVericiguat
CytokineticsOmecamtiv mecarbil
Merck & Co.Vericiguat
BayerVericiguat
Ionis PharmaceuticalsIONIS-AGT-LRx
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat
BayerVericiguat

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 16,046 patients across 17 trials

NCT05658458BayerVericiguat

A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)

Start: Dec 2022Est. completion: Sep 2024205 patients
Phase 4Completed
NCT04464525CytokineticsOmecamtiv mecarbil

Omecamtiv Mecarbil Post-trial Access Study

Start: Dec 2020Est. completion: Nov 20260
Phase 3Withdrawn
NCT06195930Merck & Co.Vericiguat

A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Start: Apr 2024Est. completion: Jul 2024106 patients
Phase 2Completed
NCT05697640BayerVericiguat

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

Start: Jun 2023Est. completion: Dec 2026104 patients
Phase 2Active Not Recruiting
NCT04836182Ionis PharmaceuticalsIONIS-AGT-LRx

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

Start: Jun 2021Est. completion: Jan 202372 patients
Phase 2Completed
NCT01951625BayerVericiguat

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Start: Nov 2013Est. completion: Jun 2015456 patients
Phase 2Completed
NCT01951638BayerVericiguat

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)

Start: Nov 2013Est. completion: Sep 2015477 patients
Phase 2Completed
NCT06474208BayerVericiguat

A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years

Start: Jul 2024Est. completion: Sep 202419 patients
Phase 1Completed
NCT03145038BayerVericiguat

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Start: May 2017Est. completion: Oct 201730 patients
Phase 1Completed
NCT06632483BayerVericiguat

An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

Start: Sep 2025Est. completion: Apr 20261,200 patients
N/AActive Not Recruiting
NCT06697353BayerVericiguat

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

Start: Nov 2024Est. completion: Sep 20254,936 patients
N/ACompleted
NCT06486844BayerVericiguat

An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany

Start: Jul 2024Est. completion: Aug 2025500 patients
N/ACompleted
NCT06363110BayerVericiguat

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

Start: Apr 2024Est. completion: Jun 20241,400 patients
N/ACompleted
NCT06148935BayerVericiguat

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

Start: Nov 2023Est. completion: Oct 20271,350 patients
N/ARecruiting
NCT05974189BayerVericiguat

The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction

Start: Jul 2023Est. completion: Oct 20241,391 patients
N/ACompleted
NCT05728502BayerVericiguat

An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China

Start: Apr 2023Est. completion: Dec 20252,400 patients
N/ACompleted
NCT05666518BayerVericiguat

A Study to Learn More About the Safety of the Drug Vericiguat in Japanese People With Chronic Heart Failure Who Will be Receiving Vericiguat Under Real-world Conditions

Start: Aug 2022Est. completion: Dec 20281,400 patients
N/ARecruiting

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 16,046 patients
4 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)